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NOVEL TREATMENTS
New Methods for Direct Delivery of
Chemotherapy for Treating Brain Tumors
Andrew J. Sawyer, Joseph M. Piepmeier, and W. Mark Saltzman*
Department of Biomedical Engineering, Yale University, New Haven, Connecticut
Despite advances in diagnostic imaging and drug discovery, primary malignant brain tumors
remain fatal. Median survival for patients with the most severe forms is rarely past eight
months. The severity of the disease and the lack of substantial improvement in patient sur-
vival demand that new approaches be explored in drug delivery to brain tumors. Recently,
local delivery of chemotherapy to brain tumors has provided a way to circumvent the blood-
brain barrier, allowing delivery of chemotherapy drugs directly to malignant cells in the brain.
Two methods of local delivery have been developed: polymeric-controlled release and con-
vection-enhanced delivery. Controlled release utilizes degradable or non-degradable poly-
mers as carriers of chemotherapy; polymer implants or microparticles are implanted locally
to introduce a sustained source of drug for periods of days or months. Convection-enhanced
delivery employs the bulk flow of drugs dissolved in fluid, which is introduced intracranially
using a catheter and pump. The convective fluid flow is capable of delivering drugs great dis-
tances within the brain, potentially treating invasive cells at a distance from the catheter in-
fusion site. These two new delivery strategies are capable of delivering both standard
chemotherapeutic drugs and new methods of anti-cancer therapy. Taken individually, or
used in tandem, they represent a potential revolution in brain cancer treatment.
INTRODUCTION
Each year, approximately 14,000 peo-
ple are stricken with brain cancer. The dis-
easeoccursacrossbothsocialandeconomic
lines, with incidence rates peaking both in
childhood and later in old age. Despite ad-
vancesinimagingtechnology— whichhas
led to earlier diagnosis of many tumors —
the ability to treat the most aggressive form
of brain cancer, glioblastoma multiforme
(GBM)†, has not improved since 1980.The
one-year survival rate for invasive central
nervoussystem(CNS)cancerwas57.9per-
cent in 2002, and survival for GBM in par-
ticular is even lower [1].
Gliomas are primary CNS tumors aris-
ing from the glial cells. Malignant gliomas
have a characteristic ability to infiltrate
healthy brain tissue and form satellite
tumors. This capacity for migration makes
themexceedinglydifficulttotreatandinvari-
ablyfatal.Evenafterresection,invasivecells
cangiverisetotumorswithincentimetersof
theresectionsite[2].Untreatedmalignanttu-
mors can eventually spread to the contralat-
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glycol; AAVs, adeno-associated vectors.eral hemisphere [3]. Many forms of systemic
chemotherapy are excluded from the CNS by
theblood-brainbarrier(BBB)[4].Afewcom-
pounds — such as the class of antiprolifera-
tive drugs called nitrosoureas (including
carmustineandlomustine)orotheralkylating
agents (temozolomide) — have some ability
to cross the BBB and have been used clini-
cally [5]. Unfortunately, systemic delivery of
these agents appears to offer modest benefit
as a supplement to radiotherapy [6,7].
Over the past two decades, a variety of
approaches to enhance the activity of system-
icallydeliveredchemotherapydrugshavebeen
tested. Hyperosmolar BBB disruption has
been used to enhance BBB transfer of
chemotherapyagents,withmixedresults.One
study,usingPETimagingtoevaluateacombi-
nationofmethotrexateandhyperosmolarBBB
disruption,indicatedanegligibleeffectinbrain
tumors,whichisechoedbythemarginalfind-
ings in clinical trials [8,9]. A variety of ap-
proacheshavebeentestedforenhancingBBB
permeability of systemically administered
drugs — by modification with hydrophobic
side groups, conjugation to ligands with
knownBBBcarriers,suchastransferrin,oren-
capsulation in liposomes or nanoparticles —
but none of these approaches have impacted
clinical treatment of glioma [10].
The failure of conventional systemic
drug delivery for glioma has motivated more
direct approaches to drug delivery. Direct in-
tracranial drug delivery would eliminate the
need for a chemotherapeutic agent to cross
the BBB. The ability to bypass the BBB
would enable a wider range of agents —
such as paclitaxel, doxorubicin, immunotox-
ins, and even gene therapy vectors — to be
evaluated for brain cancer treatment. This
review describes two of the most promising
approaches for direct delivery of agents to
intracranial tumors: polymeric-controlled re-
lease and convection-enhanced delivery.
POLYMERIC-CONTROLLED
RELEASE
Polymeric-controlled release has long
been used for drug delivery. Some early sys-
tems — the five-year subcutaneous Nor-
plant® contraceptive and the conjuctival
Ocusert® system for glaucoma — have
proven the effectiveness of this approach for
both systemic and local therapy [11]. The
controlled release of drug also protects it
from elimination [12].
Controlled release systems can be de-
signed from both degradable and non-
degradable polymers. When constructed
from nondegradable polymers, drug release
is usually governed by diffusion of the drug
through the matrix. In contrast, release from
degradable polymers is governed by a com-
bination of drug diffusion through the poly-
mer and erosion of the polymer matrix.
Polymers can be combined into copolymers
to tune degradation and release characteris-
tics. Correctly designed, polymer and drug
systems can provide reliable sustained re-
lease for periods of days or many years (see
review in [12]).
Non-degradable Polymer Systems
Delivery systems constructed from non-
degradable polymers can be employed when
a removable system is required. The most
common nondegradable polymer system is a
copolymer of ethylene and vinyl acetate.
Polyethylene-co-vinyl acetate (EVAc) mate-
rials exhibit excellent biocompatibility and
are typically implanted chronically. EVAc
have been developed for the controlled re-
lease of DNA, antibodies, as well as
chemotherapeutics [13,14].Two studies that
examined the delivery of amsacrine and mi-
toxantrone in rat glioma models observed
potent anti-tumor effects [15,16]. While the
engineering of these systems is highly de-
veloped — so that delivery systems of virtu-
ally any size, shape, rate, and duration of
release can be produced — the persistence
of the polymer after delivery limits their
clinical use.
Degradable Polymer Systems
Controlled release systems using
biodegradable polymers are more common
than non-degradable systems. The
biodegradablesystemsofferthesameadvan-
tages as the persistent wafers, but they com-
pletely erode during delivery and are cleared
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theresponsetotheimplantandmakesitclin-
ically attractive. Most systems are diffusion
regulatedandthekineticsarewell-character-
ized [17]. Many degradable systems are de-
signed to erode via hydrolysis, taking
advantage of the prevalence of water in the
human body. For example, a variety of con-
trolled release systems have been designed
around the hydrolysable anhydride bond.
Copolymers are typically coupled with an-
hydride bonds to control the rate of hydroly-
sis [12]. The addition of a copolymer affects
the degradation of the polymer device. The
correct copolymer system can achieve or-
dered erosion, which provides a consistent
release of drug. The most common copoly-
mer systems used intracranially is polybis(p-
carboxyphenoxy)propane-sebacic acid
(p(CPP-SA).
p(CPP-SA)-based delivery systems
have been characterized for a variety of
drugs and already are used clinically. Many
controlled release systems are based on an
implantable wafer, which has been studied
with the drugs mitoxantrone, carmustine
(BCNU), 4-hydroperoxycyclophosphamide
(4-HC), paclitaxel, carboplatin, and adri-
amycin [18-21]. The characteristics of drug
release from wafers depend on the polymer
and drug used. A typical controlled release
curve for BCNU is shown in Figure 1 [22].
The linear region in Figure 1b indicates that
the drug release is diffusion controlled [12].
In drug-polymer systems with a high degree
of surface associated drug, a burst release
phase is observed. p(CPP-SA) wafers of
BCNU and 4-HC have demonstrated release
for 50 days. The release of paclitaxel pro-
ceeded at a much lower rate, less than 0.01
mg/day, and for a much longer period of
time (160 days).The slower release rate can
be attributed to the hydrophobicity of the
drug that causes a strong affinity for the
polymer. The controlled release of drugs
from these wafers has demonstrated per-
formance in many in vitro and in vivo
glioma models. Studies have demonstrated
improved performance of these wafers when
compared to free drug administration in a rat
model challenged with an intracranial 9L
tumor [23]. Small cylindrical wafers have
been studied in the same way [18].
The p(CPP-SA) wafer loaded with
BCNU has undergone further characteriza-
tion and is available clinically as Gliadel®
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Figure 1: The cumulative release of BCNU into a well-stirred reservoir as a function of
time (a) and the square root of time (b). The linear portion indicated in b is indicative of
diffusion controlled release from a planar geometry. Reprinted with permission from Springer
Science and Business Media: Fung, L. K. et al. Chemotherapeutic drugs released from poly-
mers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Figure 2. Pharma-
ceutical Research. 1996;13:671-82.[24].The Gliadel® wafer is 14 mm in diam-
eter and 1 mm thick. It is loaded with 7.7 mg
of the drug carmustine and is implanted in-
tracranially after surgical debulking of the
tumor (Figure 2). Gliadel® has been studied
for clinical use in initial treatment, treatment
of recurrences, and in conjunction with ra-
diotherapy for malignant gliomas [25-27].
In all cases, therapy with Gliadel® was well
tolerated with no significant increase in tox-
icity, infection, or inflammation.The major-
ity of studies indicated a modest
improvement in survival for patients with
malignant gliomas that received Gliadel®
[28,29]. Further research is directed at im-
proving the Gliadel® wafer by examining
dosing and combination therapy [30].
Fatty acid dimer copolymers use the
same polyanhydride linkages, but they offer
a distinct advantage over carboxyphenoxy
propane polymer systems. FAD-SA is typi-
cally formed into a disk shape and then im-
planted intracranially. The primary use of
FAD-SA is the controlled delivery of the
drug 4-hydroperoxycyclophosphamide
(4HC) [31]. FAD-SAis used for delivery of
this drug because 4-HC is hydrolytically un-
stable in the p(CPP-SA) wafer [32]. The
ability to tailor the chemical and physical
properties of the vehicle to the drug is one
of the advantages of polymeric delivery.
Other degradable polymers are also
useful for drug delivery. Biodegradable
polymer matrices based on polymers of lac-
tide and glycolide are perhaps the most pop-
ular platform for local drug delivery.
Polylactic acid (PLA), polyglycolic acid
(PGA), and their copolymer polylactic-co-
glycolic acid (PLGA) have a long history of
use as biomaterials, beginning in the 1970s
with biodegradable sutures. Matrices made
from these polymers are biocompatible, hy-
drophobic, and degrade to the naturally oc-
curring monomers via ester hydrolysis.
Polymer nanospheres, microspheres, and
wafers of varying sizes are made via emul-
sion/solvent evaporation, salt leaching, and
other methods [33].When making spherical
particles using the emulsion process, the sol-
vent, surfactant, and polymer properties can
be modified to tune size and release charac-
teristics [34,35].
Implantable PLGA matrices loaded
with chemotherapeutics are currently under
development. The implants can be in the
form of electrospun scaffolds, thin films, or
even wafers.The process of electrospinning
uses a voltage differential to produce a non-
woven mesh. Paclitaxel has been mixed with
the polymer solution before electrospinning
to create a mesh with drug-delivery capabil-
ity [36]. The drug-loaded mesh has con-
trolled release properties and was effective
in vitro against C6 glioma cells.Amesh de-
livery system might have advantages over a
wafer, because the mesh can potentially con-
form to the shape of the resection cavity.
The C6 glioma line was also used to evalu-
ate the controlled release of radioiodo-
deoxyuridine from a thin film of PLGA[37].
Biodegradable PLGA wafers containing
BCNU can be used in an analogous method
to Gliadel®. The release profile of BCNU
Figure 2: Intracranial placement of Gli-
adel® wafer. The wafer is implanted in the
cavity left after surgical resection of the
tumor. Wafers are dime-sized and impreg-
nated with carmustine. Reprinted with per-
mission from Fleming. Pharmacokinetics of
the carmustine implant. Clinical Pharmacoki-
netics. 2002;4(6):403-419 (Figure 1, page
405).
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file and duration when compared to the
p(CPP-SA) wafer [38]. A reformulated
wafer made of compressed BCNU contain-
ing microparticles yielded a longer in vitro
release profile, 70 days compared to seven
[39].
PLGAnanoparticles and microparticles
can be fabricated using the single emulsion
method to encapsulate hydrophobic com-
pounds and the double emulsion method to
encapsulate hydrophilic compounds (Figure
3) [40,41]. The advantages of polymer par-
ticles lie in the route of administration.
Polymer nanoparticles may be administered
using a burr hold and catheter, which is sig-
nificantly less invasive than the implantation
of polymer wafers.
Polymeric-controlled release is able to
administer drugs intracranially, which would
be excluded for systemic use or as a new
route of administration.This is the case with
doxorubicin (adriamycin), which exhibits
dose-limiting cardiotoxicity [42]. The drug
temozolomide (TM) has demonstrated clin-
ical efficacy when given systemically [5].A
controlled release form of TM using PLGA
microparticles gave the characteristic bipha-
sic release profile, burst release followed by
a linear period, with a 35-day release period
[43]. The TM microparticles demonstrated
cytotoxicity in culture with C6 cells and
could be administered intracranially as part
of the same regimens currently evaluating
systemic TM.
Polymeric-controlled release systems
can be engineered for drugs, such as pacli-
taxel, that are difficult to administer with
conventional methods. Two drug properties
that can limit traditional use are hydropho-
bicity and toxicity. Paclitaxel is hydrophobic
and sparingly soluble in water; this restricts
its use in injection buffers. Intravenous
chemotherapy with paclitaxel utilizes an ad-
juvant called Cremophor EL to disperse the
drug, which can cause serious side effects.
PLGA is naturally hydrophobic and encap-
sulates hydrophobic drugs efficiently. The
hydrophobicity of a drug also affects its re-
lease profile. Paclitaxel preferentially parti-
tions inside PLGA and exhibits a lengthy
release curve.Astudy with PLGAmicropar-
ticles showed a sustained release of pacli-
taxel for more than 60 days without a burst
release period [44]. The controlled release
of paclitaxel also limits the systemic toxic-
ity. The release is so slow that a variety of
coencapsulants have been evaluated to
quicken the release of paclitaxel from PLGA
matrices. Two examples are isopropyl
myristate and vitamin E TPGS [45,46].
Both emulsifiers produced a burst release
period. The formulation using vitamin E
TPGS decreased the release time compared
to particles made with the surfactant
poly(vinyl alcohol) (PVA) [47].
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Figure 3: SEM image
of PLGA microparti-
cles loaded with
BCNU. The particles
were formed using the
solvent extraction/evap-
oration method. Aver-
age sphere diameter is
30 ﾵm. Reprinted with
permission from Else-
vier. Painbeni T, et al.,
Internal morphology of
poly(D,L-lactide-co-gly-
colide) BCNU-loaded
microspheres. Influ-
ence on drug stability.
European Journal of
Pharmaceutics and
Biopharmaceutics.
1998;45:31-9.Controlled release systems may be par-
ticularly useful for agents produced by
biotechnology, such as the proteins and nu-
cleic acids that are needed for immunother-
apy or gene therapy. The rare instances of
complete recovery from malignant gliomas
typically have been attributed to an immune
response. This observation triggered the
search for compounds that could cause im-
mune cell-mediated cytotoxicity. Type 1 in-
terferons show antitiumor activity but have
a short half-life and high dose toxicity [48].
The short half-life necessitates a continuous
delivery for the molecule to be active, but
the continuous delivery will pose the risk of
side effects. Encapsulating these agents pro-
tects them from elimination and provides a
means to control the amount released. Inter-
leukin-18, which can be used in this manner,
can be encapsulated in PLGAmicrospheres
and is active upon release [49]. PLGA can
also encapsulate and release viable aden-
ovirus [50].The controlled release approach
improved in vivo efficacy.
Polymeric-controlled release provides a
biocompatible, tunable platform in which
drug loading, release rate, longevity, and
form can be altered via polymer combina-
tion and processing.The method of delivery,
as witnessed by Gliadel®, adds minimal
complexity, requires no additional surgical
procedures, and minimizes solubility limita-
tions. Furthermore, the controlled release of
the drug slows elimination and increases du-
ration of exposure. This increases the
amount of drug administered without expos-
ing the tissue to high concentrations that
could cause tissue damage. Most impor-
tantly, polymeric-controlled release has a
clinical history of beneficial use.
Whilecontrolledreleasesystemscande-
liver drugs for long periods of time locally in
the brain, local penetration of the drug is fre-
quently limited by diffusion [21]. When low
diffusioncoefficientsarecoupledwithahigh
rateofelimination,drugdistancefromthede-
livery locus can be limited to millimeters
[51]. The extracellular matrix (ECM) of the
brainalsoimposesitsownlimitsondiffusive
transport.TheECMofthebrainisahydrated
environment with a low volume fraction, a
high degree of tortuosity, and small pore size
[52-55]. The local environment of a tumor
limits diffusion even further [56]. These fac-
tors conspire to confine a high drug concen-
tration to within 3 mm of the delivery site
[24]. This distance is exceeded by invasive
glioma. Controlled release also is limited by
size. The polymer delivery system must be
large enough or be used in enough amount to
deliver clinically relevant drug dosage.
CONVECTION-ENHANCED
DELIVERY
Convection-enhanced delivery (CED)
was developed to deliver compounds
throughout the brain to overcome the diffu-
sion barrier seen with polymeric-controlled
release [57]. CED utilizes an applied exter-
nal pressure gradient to induce fluid convec-
tion in the brain. Fluid is typically
administered via a small catheter using a
pump [58]. Because moderately high pres-
sures (up to 70 mmHg) must be used to
drive convective flows, such procedures are
plagued by backflow along the catheter and
often subject the tissue to high pressures.
The increase in pressure is due to occlusions
that may block the catheter from delivering
an adequate flow rate. The use of microfab-
ricated silicon probes reduces those con-
cerns and improves on the general delivery
method [59].The outlet of the silicon probes
is along an axis perpendicular to the inser-
tion direction; this geometry prevents tissue
from plugging the orifice. Acontrolled pres-
sure source in stream with a fluid reservoir
ensures operation at constant pressure. This
prevents the pressure spikes that accompany
constant volume delivery. An added advan-
tage to constant pressure delivery is the ease
with which fluid properties can be deter-
mined using simple mathematical models.
CED and Drug Delivery
The main benefit to administering drug
via CED is the greater distribution volume.
Studies that have compared a bolus injection
toCEDhavenotedalargerdistributionanda
greaterefficacy[60,61].Thebenefitsarede-
rived from the greater distribution and a con-
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The technique is inherently flexible and can
be used in chemotherapy, gene therapy, and
immune therapy. Methods of drug delivery
using free drug have been studied in animals
andclinically.Thedrugsadministeredrunthe
gamutfromnontraditionalcompoundstotyp-
ical chemotheraputic drugs. Typical clinical
use of CED is for salvage therapy after a re-
currence of glioma and follows one of two
protocols. Patients are either given local in-
fusions after surgical resection or given infu-
sions directly into the tumor. Drugs used
clinicallyincludebothtargetedtoxinsandtra-
ditionalchemotherapeutics(Table1).Studies
using the drug paclitaxel have observed the
highest response rates, which are around 75
percent. Typical response rates for targeted
toxin treatment were lower [62]. Response
rate and the occurrence of adverse events
have been observed to be dose dependent
[63].OngoingclinicaltrialsincludetheCED
ofIL13-PE38QQ,andtheCEDoftopotecan.
The drugs listed in Table 1 reflect only
a small sample of the therapeutic agents that
have been evaluated in animal models —
which include the traditional chemotherapy
drugs BCNU and topotecan [64,65]. How-
ever, the drugs available for delivery via
CED are still limited by solubility.Away to
avoid solubility issues and protect antineo-
plastic agents from elimination is to encap-
sulate them. Recent research studied
nanoliposomal encapsulated CPT-11 in a rat
glioma model [66]. The study showed that
CPT-11 benefited from the increased distri-
bution via CED and a longer residence time.
Large particles, with severely restricted
diffusion, stand to benefit most from CED.
Accordingly, several research groups are de-
termining and improving the penetration of
particles within the brain delivered via CED
(Figure 4). Studies looking at the size of par-
ticleinfusateconcludedthatsmallerparticles,
around 20 nm, distributed further than larger
particles [67]. The same behavior was ob-
served using liposomes [68]. Interestingly,
particles 40nm and larger had similarly re-
stricted distributions. The surface properties
ofthesmallparticlesplayasignificantrolein
their volume distribution. Surfaces that were
neutral, negatively charged, or coated with
poly(ethyleneglycol)(PEG)orbovineserum
albumin (BSA) maximized distribution vol-
ume [69]. Coatings that were positively
charged severely restricted particle distribu-
tion. Adjuvants have been used to improve
distribution regardless of particle properties.
Ahyperosmolar infusion of mannitol signifi-
cantly increased volume distribution [68].
When the infusate experiences specific cell
binding,aninfusionofexcessunencapsulated
ligands can increase the distribution [70].
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Table 1: Therapeutic agents evaluated in
clinical trials for glioma treatment.
TF-CRM107
cpIL-4-PE
IL13-PE38QQR
TGFʱ-PE38 (TP-38)
LIPO-HSV-1-tk
Paclitaxel
Cotara®
Adapted from [62].
Figure 4: 20 nm Polystyrene beads de-
livered via CED into the caudate of a rat.
Image shows local nanoparticle penetration
after a 5 ﾵL infusion (Sawyer AJ, Neeves
KB, Foley CP, Olbricht WL, and Saltzman
WM, unpublished data).One objective of the previous particle in-
fusionstudieswastomodelthedeliveryofei-
ther viral vectors that could be used for gene
therapy or drug loaded particles. CED has the
potential to improve gene therapy by increas-
ing the available concentration of vectors.
Two studies looked at the distribution of
adeno-associatedvectors(AAVs)administered
via CED [71,72]. Each realized a greater and
more homogeneous distribution of transduc-
tion by combining AAVs with CED, which
was further improved with adjuvant heparin.
CED and Imaging
CED has the ability to improve both the
imaging and treatment of brain tumors. This
allows for a combination approach that can
monitor the distribution of drugs as they are
being delivered [73].To observe the distribu-
tionviaCED,liposomeswerelabeledwiththe
MRIcontrastagentgadolinium. Thegadolin-
iumliposomescanthenbeinfusedwithparti-
clesofsimilarsizeandmonitoredusingMRI.
This approach was validated in a primate
model [74]. The distributions observed via
MRI completely coincided with distributions
determinedusingfluorescence.Administering
contrast agent along with chemotherapeutic
drugsallowsfortheinitialvolumedistribution
to be observed and for tissue necrosis to be
monitored within that distribution area [75].
CEDislimitedbyitsinvasivenessandby
theanatomicalinfluencesondrugdistribution.
CED requires the insertion of a catheter sev-
eralcentimetersdeepintothebrain,whichcan
cause tissue damage and may induce air bub-
bles[76].Theanatomyofthebrainaffectsthe
distributionofdrugs.Whitemattertrackspro-
vide areas of comparatively high fluid con-
ductivity. If the catheter is inserted through
white matter, for example the corpus callo-
sum,thehighconductivitycombinedwithre-
flux up the catheter siphons drug away from
parenchyma. The perivascular spaces have
also been observed to collect infusate during
CED[77].Theunpredictableflowcanleadto
collection of drug either in the perivascular
spaces, wound track, or under the scalp. This
has caused incidences of edema and wound
dehiscence. The localized high dose area
caused the same symptoms during the deliv-
ery of viral vectors [78].
Clinical Trials
A Phase III randomized clinical trial
(PRECISE TRIAL) comparing the outcome
between Gliadel and CED of IL13-
PE38QQR has been completed (unpublished
data). This study randomized patients with
GBM for treatment after they had failed con-
ventional therapy (surgery, radiotherapy, +/-
chemotherapy). This study revealed no sig-
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Table 2: Advantages and disadvantages of polymeric-controlled release and
convection-enhanced drug delivery.
Advantages Disadvantages
• Sustained drug release • Poor drug penetration
• Define release kinetics • Drug dosage limited
• Tunable release properties by implant size
Polymeric-controlled • Low invasiveness
release • Low peak drug release limits
tissue damage
• Biocompatible
• Localized delivery
• Large drug distribution volume • Invasive
• Flexible therapy protocol • Long infusion times
Convection-enhanced • Consistent drug concentration • Potential high
delivery intracranial pressures
• Unpredictable drug
distributionnificant difference in outcome. Median sur-
vival following tumor recurrence was 35.3
weeks for the Gliadel and 36.4 weeks for
IL13-PE38QQR.Itisanticipatedthatinaccu-
ratecatheterplacementandunresolvedprob-
lems with adequate drug distribution may
havecontributedtotheabsenceofbenefitfor
theCEDarm.Thesedatasupporttheneedfor
continued research in improving drug distri-
bution and better delivery methods.
CONCLUSIONS
Local delivery to brain tumors can be
accomplished using the two strategies of
polymeric-controlled release and convec-
tion-enhanced delivery. Each technique
strives to address the need for controllable
intracranial drugdelivery.Thetwo technolo-
gies offer unique benefits and suffer distinc-
tive limitations, which are listed in Table 2.
The principle disadvantage to controlled re-
lease is the restricted drug distribution. The
limitations imposed by diffusion within the
brain limit drug penetration to a region
smaller than the typical invasive area of ma-
lignant gliomas.
CED’s strength lies in the potential for
large distribution volume of infused drugs.
Thelonginfusiontimesandunpredictabledis-
tribution have also caused an abundance of
sideeffectsinrecentclinicaltrials.Trialsusing
paclitaxel have noticed a high rate of drug re-
lated adverse events that include wound de-
hiscence, inflammation, and edema [79,80].
Thesesideeffectsareattributedtodrugback-
flow along the catheter, and drug localization
in the perivascular and subarachnoid spaces.
Infusing an encapsulated drug may decrease
the incidence of these adverse events.
OUTLOOK
CED was developed as a method to ad-
dress the shortcomings of polymeric-con-
trolled release. Coincidentally, many of the
flaws in CED are the strengths of a poly-
meric-controlled release approach. Encapsu-
lation of drug would limit the reflux and
promote better wound healing after delivery.
Delivering encapsulated drug could shorten
the infusion time. A shorter infusion time
would deliver a lower maximum drug con-
centration which could address the instances
of edema and inflammation. Moreover, a
combined treatment strategy could truly lo-
calize the delivery by restricting it to a pre-
scribed area. Nanoparticle technology has
advanced such that high levels of targeting
ligand can be expressed on the surface of the
degradable particles [81]. These particles
could then be targeted to a subpopulation of
cells.
Acombined approach is not without its
potential pitfalls. The polymer particles
would have to be large enough to deliver a
clinically relevant dose.The increase in size
could restrict the distribution of particles in
the parenchyma. While the adjuvants could
improve the distribution, a multi-focal de-
livery strategy may be necessary to circum-
vent the transport limitations.
Local delivery to brain tumors has al-
ready provided a modest increase in survival
when used in addition to surgery and radio-
therapy. Despite the advances, GBM re-
mains fatal regardless of the mode of
treatment.Thereisuntappedpotentialinboth
of the local delivery strategies discussed
here. Polymeric-controlled release and CED
can be used as techniques to administer the
standard agents, combinations of drugs, as
well as new methods of anti-tumor therapy.
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